Drug Patents owned by Ucb Inc

1. List of Briviact drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6911461 UCB INC 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
Feb, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10729653 UCB INC Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives
Apr, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Aug 27, 2024

Drugs and Companies using BRIVARACETAM ingredient

Market Authorisation Date: 12 May, 2016

Treatment: Treatment of partial-onset seizures as adjunctive therapy in patients with epilepsy aged 16 years and older with epilepsy; Treatment of partial onset seizures in patients with epilepsy aged 16 years and older with epilepsy

Dosage: TABLET;ORAL

How can I launch a generic of BRIVIACT before it's patent expiration?
More Information on Dosage

2. List of Keppra drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8802142 UCB INC Pharmaceutical compositions comprising levetiracetam and process for their preparation
Jun, 2031

(8 years from now)

US8802142

(Pediatric)

UCB INC Pharmaceutical compositions comprising levetiracetam and process for their preparation
Dec, 2031

(8 years from now)

Drugs and Companies using LEVETIRACETAM ingredient

Market Authorisation Date: 30 November, 1999

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of KEPPRA before it's patent expiration?
More Information on Dosage

3. List of Keppra Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7858122 UCB INC Extended release formulation of levetiracetam
Sep, 2028

(5 years from now)

Drugs and Companies using LEVETIRACETAM ingredient

Market Authorisation Date: 12 September, 2008

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of KEPPRA XR before it's patent expiration?
More Information on Dosage

4. List of Nayzilam drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9687495 UCB INC Methods and systems for the delivery of a therapeutic agent
Jan, 2028

(4 years from now)

US9289432 UCB INC Methods and compositions for the delivery of a therapeutic agent
Jan, 2028

(4 years from now)

US8217033 UCB INC Methods and compositions for the delivery of a therapeutic agent
Jan, 2028

(4 years from now)

US8809322 UCB INC Methods and compositions for the delivery of a therapeutic agent
Jan, 2028

(4 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) May 21, 2022
Orphan Drug Exclusivity (ODE) May 17, 2026

Drugs and Companies using MIDAZOLAM ingredient

Market Authorisation Date: 17 May, 2019

Treatment: Acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 12 years of age and older

Dosage: SPRAY;NASAL

How can I launch a generic of NAYZILAM before it's patent expiration?
More Information on Dosage

5. List of Neupro drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8617591 UCB INC Transdermal delivery system for the administration of rotigotine
Jul, 2023

(5 months from now)

US8246980 UCB INC Transdermal delivery system
Nov, 2025

(2 years from now)

US8246979 UCB INC Transdermal delivery system for the administration of rotigotine
Sep, 2027

(4 years from now)

US10130589 UCB INC Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
Dec, 2030

(7 years from now)

US10350174 UCB INC Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
Dec, 2030

(7 years from now)

US9925150 UCB INC Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
Mar, 2032

(9 years from now)

Drugs and Companies using ROTIGOTINE ingredient

Market Authorisation Date: 09 May, 2007

Treatment: A method for the treatment of a patient suffering from a disease treatable with rotigotine, comprising applying the claimed transdermal delivery system (tds) to the skin of the patient; Treatment of signs and symptoms of parkinson's disease by application of claimed transdermal system; Treatment of restless legs syndrome by application of claimed transdermal delivery system

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

How can I launch a generic of NEUPRO before it's patent expiration?
More Information on Dosage

6. List of Vimpat drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE38551 UCB INC Anticonvulsant enantiomeric amino acid derivatives
Mar, 2022

(10 months ago)

Exclusivity Exclusivity Expiration
New Indication (I) Nov 16, 2023
New Patient Population (NPP) Oct 14, 2024

Drugs and Companies using LACOSAMIDE ingredient

Market Authorisation Date: 28 October, 2008

Treatment: Method of treating partial onset seizures in patients 4 years of age and older; Method of treating, as initial loading dose for monotherapy or adjunctive therapy, partial onset-seizures in a patient with epilepsy aged 17 years or older; Method of use of treating, as an initial loading dose for monotherapy or adjunctive therapy in partial onset seizure patients with epilepsy aged 17 years or older; Method of use as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older; Method of use for treatment of partial-onset seizures in patients 4 years of age and older

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of VIMPAT before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic